NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
07/30/2024
Back to search
Official data from USPTO
NEURACTHEL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NEURACTHEL
ST13
US500000079348994Class
3, 5, 10
Filing
79348994
Registration
7265343
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
07/30/2024
Trademark type
Word
Nice classes
3, 5, 10
Filing date
04/07/2022
Registration date
01/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/09/2024
Last transaction
01/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
IE
Examiner
KING, LINDA
Current location
Historical data usage
Holders and representatives
Holders
Clinuvel Europe Ltd
Representatives
Mark M. Friedman Dr. Mark Friedman Ltd.
Technical classification
Nice Classes
Class 3Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 3
Non-medicated cosmetics; cosmetics for protecting against light and UV; cosmeticscosmetic products as leave-onlotionscreamsointments and other formulations as well as cosmetic products for topical use; non-medicated *skin care* preparations for protecting the skin against light and UV; non-medicated skin *care* photoprotection preparations; *non-medicated* sun care preparations for cosmetic use; sun-tanning preparations; *cosmetic* suntan lotions; suntan oils *for cosmetic purposes;* tanning gels; cosmetic preparations for skin care containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetics for tanning the skin containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetic preparations for tanning the skin without sunlight containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; sun screen preparations; cosmetic preparations for protecting the skin from the sun's rays; cosmetics for protecting the skin from sunburn; sun protecting creams; sun *block preparations;* sun block; sun blocking preparations; sun-block lotions; sun blocking oils; SPF sun block sprays; *lip balm with sun block;* sun blocking lipsticks; *cosmetic sunscreen preparations;* waterproof sunscreen *preparations;* water-resistant sunscreen *preparations;* sunscreen preparations; sunscreen creams; sunscreen lotions; sunscreen sticks; cosmetic foams containing sunscreen *preparations; sunscreen* preparations for protecting the hair from the sun; *nonmedicated cosmetic preparations against sunburns;* non-medicated *sun care preparations* for skin care after exposure to the sun's rays.
Class 5
Pharmaceuticals *for the prevention and treatment of neurologicalendocrinologicaldegenerative disorders;* pharmaceutical drugs *for the prevention and treatment of epidermal problemsdamaged skin and tissue;* pharmaceutical products for endocrineneuroendocrinesystemicinflammatoryacute disorders such as sepsisshockhaemorrhagic shockacute bleeding disorderschronic disorders requiring preventioncurative or palliative treatment where no other treatments are effective or safe; pharmaceutical preparations *for the prevention and treatment of viralmetabolicgeneticendocrinemusculoskeletalophthalmiccardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricimmune system related diseases and disorders;* pharmaceuticals used for cerebrovascular accidents *in the nature of strokes*; pharmaceutical preparations for the prevention and treatment of arterial ischemic strokes; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the prevention and treatment of cardiovascular and cerebrovascular diseases; cardiovascular drugs for use in treating hypertension; cardiovascular preparations *for the prevention and treatment of cardiometabolic conditions;* cardiovascular pharmaceuticals *for the prevention and treatment of ischemic syndromes;* cardiovascular pharmaceutical preparations *for the prevention and treatment of cardiomyopathies;* cardiovascular agents for medical purposes; cardiovascular drugs used in treating *cardiogenic shocks;* cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; medicated sun care preparationssun tanning preparations for pharmaceutical purposes containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; *dermatologicalsdermatological preparationsdermatological pharmaceutical substancesdermatological pharmaceutical products;* medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated *skin care* creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; *medicated chemical and biological skin care preparations and chemical reagents* for medical purposes which contain analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; *drug afamelanotide in aqueous and gel formulations;* pharmaceutical implants *comprising living tissue;* subcutaneous implants containing *living tissue and also containing* afamelanotide; implantable *subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the prevention and treatment of neurologicalendocrinologicaldegenerative disorders; implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations and containing afamelanotide for the prevention and treatment of skin related diseases and disorder*
Class 10
Medical apparatusdevices and instruments *for accessing subcutaneous structures of the human body for the purpose of administering medical treatment;* apparatus for drug administration*namelydrug delivery catheters;* devices for use in the administration of pharmaceuticalsimplantable drug delivery ports; controlled rate release apparatus for dispensing pharmaceutical substances*namelyimplantable drug delivery pumps;* medical fluid injectors; injection syringes; medical syringes; implantable subcutaneous drug delivery *ports and pumps*
Publications
History of USPTO decisions and trademark events.
33 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/14/2024
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
06/25/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/25/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/24/2024
FIMP
FINAL DISPOSITION PROCESSED
06/24/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
01/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
10/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/24/2023
PUBO
PUBLISHED FOR OPPOSITION
10/24/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/15/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/14/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/14/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/14/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/14/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/14/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/14/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/14/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/14/2023
RFNT
REFUSAL PROCESSED BY IB
04/20/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/28/2023
RFRR
REFUSAL PROCESSED BY MPU
03/28/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/02/2023
CNRT
NON-FINAL ACTION WRITTEN
02/01/2023
DOCK
ASSIGNED TO EXAMINER
01/25/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/13/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/08/2022
Continuous trademark protection
Get notified about every new filing that threatens NEURACTHEL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.